Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. |
| Hydrocodone | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. |
| Magnesium sulfate | The therapeutic efficacy of Alphaprodine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Alphaprodine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. |
| Orphenadrine | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. |
| Pramipexole | Alphaprodine may increase the sedative activities of Pramipexole. |
| Ropinirole | Alphaprodine may increase the sedative activities of Ropinirole. |
| Rotigotine | Alphaprodine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Alphaprodine. |
| Sodium oxybate | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. |
| Thalidomide | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Alphaprodine is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Alphaprodine is combined with Desmopressin. |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Alphaprodine. |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Alphaprodine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alphaprodine. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Alphaprodine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Alphaprodine. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alphaprodine. |
| Naltrexone | The therapeutic efficacy of Alphaprodine can be decreased when used in combination with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Alphaprodine. |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Alphaprodine. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Alphaprodine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Alphaprodine. |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Alphaprodine. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alphaprodine. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Alphaprodine. |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Alphaprodine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Alphaprodine. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Alphaprodine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Diamorphine is combined with Alphaprodine. |
| Bezitramide | The risk or severity of adverse effects can be increased when Bezitramide is combined with Alphaprodine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alphaprodine. |
| Etorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Alphaprodine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Alphaprodine. |
| Desomorphine | The risk or severity of adverse effects can be increased when Desomorphine is combined with Alphaprodine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Carfentanil is combined with Alphaprodine. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alphaprodine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Alphaprodine. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alphaprodine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Alphaprodine. |
| DPDPE | The risk or severity of adverse effects can be increased when DPDPE is combined with Alphaprodine. |
| Lofentanil | The risk or severity of adverse effects can be increased when Lofentanil is combined with Alphaprodine. |
| Opium | The risk or severity of adverse effects can be increased when Opium is combined with Alphaprodine. |
| Normethadone | The risk or severity of adverse effects can be increased when Normethadone is combined with Alphaprodine. |
| Piritramide | The risk or severity of adverse effects can be increased when Piritramide is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Alphaprodine is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of Alphaprodine can be decreased when used in combination with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Alphaprodine is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Alphaprodine is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Alphaprodine is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Alphaprodine is combined with Carfentanil, C-11. |
| Naloxegol | The risk or severity of adverse effects can be increased when Naloxegol is combined with Alphaprodine. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Alphaprodine is combined with Benzhydrocodone. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphaprodine. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Alphaprodine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Alphaprodine. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Alphaprodine. |
| Mirtazapine | Alphaprodine may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Sibutramine. |
| Nefazodone | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Nefazodone. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Alphaprodine. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Alaproclate. |
| Ethanol | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Alphaprodine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine. |
| Phentermine | Phentermine may increase the analgesic activities of Alphaprodine. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Alphaprodine. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Alphaprodine. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Alphaprodine. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Alphaprodine. |
| MMDA | MMDA may increase the analgesic activities of Alphaprodine. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Alphaprodine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Alphaprodine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Alphaprodine. |